Glucosamine has become one of the world’s most popular dietary supplements. Many people take it daily to ease joint discomfort, maintain cartilage health, and remain active as they grow older.
Because it has been available for years and is widely sold without a prescription, glucosamine is often viewed as a harmless addition to a healthy lifestyle.
A new study from the University of Florida is challenging that assumption. Researchers report that glucosamine use may be linked to a higher risk of worsening cognitive decline in people already experiencing memory problems. Their findings were published in Nature Metabolism.
The research focuses on Alzheimer’s disease, a condition that affects memory, reasoning, and daily functioning. Alzheimer’s disease is the leading cause of dementia and currently affects millions of people worldwide.
Despite major advances in neuroscience, scientists still do not fully understand why some people develop Alzheimer’s disease or why the condition progresses more rapidly in certain individuals.
One area of growing interest is metabolism, the collection of chemical processes that allow cells to produce energy and perform essential functions. Scientists increasingly suspect that metabolic changes play an important role in brain aging and neurodegenerative diseases.
The University of Florida team investigated whether glucosamine could influence these processes. Although glucosamine is primarily known for its role in joint health, researchers pointed out that it can cross the blood-brain barrier and enter the central nervous system.
This means that glucosamine may affect brain cells directly rather than acting only in joints and connective tissues.
To explore this possibility, researchers analyzed medical records collected between 2012 and 2024 from the University of Florida health care system. Using advanced artificial intelligence tools, they searched for relationships between glucosamine use and cognitive decline.
The analysis revealed a striking pattern. Patients taking glucosamine appeared to be 25 percent more likely to progress from mild cognitive impairment to dementia and Alzheimer’s disease compared with non-users.
Mild cognitive impairment is often considered an intermediate stage between normal age-related forgetfulness and dementia. People with mild cognitive impairment experience noticeable memory or thinking problems, but they can usually still function independently. However, some individuals eventually develop Alzheimer’s disease or other forms of dementia.
The study also found that people already diagnosed with Alzheimer’s disease or dementia who used glucosamine had approximately a 25 percent greater risk of death during the study period.
Researchers then investigated what might explain these observations. They focused on a biological process involving sugar molecules attached to proteins inside cells.
Proteins act as the machinery that keeps cells alive and functioning. To work properly, many proteins require small chemical modifications. One common modification involves attaching sugar molecules, which helps proteins fold into the correct shape and perform their tasks.
The researchers discovered evidence suggesting that this sugar-modification system becomes excessively active in Alzheimer’s disease. Rather than helping cells, excessive sugar tagging may contribute to harmful changes in brain tissue.
Experiments in genetically engineered mice provided additional evidence. Animals given glucosamine showed increased sugar modification of proteins and developed memory impairments. When researchers reduced this sugar-tagging process, memory performance improved.
Further support came from human brain samples stored at the University of Florida’s brain and tissue bank. Researchers observed elevated levels of sugar-modified proteins in Alzheimer’s disease brain tissue, suggesting that the same biological pathway may operate in humans.
These findings led the researchers to propose that glucosamine may amplify a metabolic process already overactive in Alzheimer’s disease. This could potentially accelerate disease progression in susceptible individuals.
Despite the concerning results, experts stress that the study does not prove glucosamine causes Alzheimer’s disease. Observational studies can identify associations but cannot establish direct causation. Many factors influence dementia risk, including genetics, cardiovascular health, lifestyle habits, education, and other medical conditions.
The research nevertheless has several strengths. It combines large-scale human data analysis with laboratory experiments, animal studies, and direct examination of human brain tissue. This multi-layered approach strengthens confidence that the observed biological mechanisms deserve serious attention.
At the same time, significant questions remain unanswered. Researchers do not yet know whether all glucosamine products carry similar risks. They also do not know whether certain individuals may be more vulnerable than others or whether the effects vary according to dosage and duration of use.
Future studies will be needed to confirm the findings and determine whether changes in supplement use can alter the course of cognitive decline.
The study serves as an important reminder that dietary supplements are biologically active substances. Even products considered natural can affect complex systems throughout the body. As scientists continue searching for ways to prevent and treat Alzheimer’s disease, understanding these effects becomes increasingly important.
The study’s findings are thought-provoking because they point toward metabolism as a potentially important driver of Alzheimer’s disease progression. If future research confirms these results, targeting metabolic pathways could become an important addition to current treatment strategies that focus primarily on amyloid plaques and tau tangles.
For now, people taking glucosamine should not make sudden decisions based on a single study. Instead, individuals concerned about memory problems, dementia risk, or supplement use should discuss the findings with their healthcare professionals.
Further research will determine whether glucosamine truly influences Alzheimer’s progression or whether the association reflects other underlying factors.
If you care about Alzheimer’s disease, please read studies about vitamin D deficiency linked to Alzheimer’s and dementia, and strawberries can be good defence against Alzheimer’s.
For more health information, please see recent studies about foods that reduce Alzheimer’s risk, and oral cannabis extract may help reduce Alzheimer’s symptoms.
Source: University of Florida.
